Every year, MIT Technology Review undertakes the daunting task of surveying the global landscape of science and technology to identify the "Innovators Under 35"—a cohort of brilliant minds whose research, tenacity, and technical prowess are poised to redefine the limits of human capability. This year’s list is particularly notable for its heavy concentration on biotechnology, featuring nine trailblazers who are shifting the paradigm of medicine.
From lifesaving interventions in maternal health to the high-stakes world of cellular age-reversal, these innovators are not merely conducting research; they are architecting the future of healthcare. This report examines five of these visionaries, detailing how their work—ranging from traditional artistic inspiration to cutting-edge generative AI—is addressing some of the most stubborn challenges in modern science.
1. Paschal Kija: Democratizing Maternal Survival
In Tanzania, postpartum hemorrhage (PPH) remains a leading cause of maternal mortality, accounting for approximately 29% of maternal deaths. It is a preventable tragedy that often occurs in environments lacking access to advanced surgical interventions. Paschal Kija, a 28-year-old innovator, has engineered a solution that is as elegant as it is affordable: the Mkanda Salama, or "Safe Wrap."
The Mechanics of the Safe Wrap
The device operates on a simple, pressure-based principle to stem uncontrolled bleeding following childbirth. At a price point of just $70, it is designed for deployment in low-resource settings where the high costs of conventional medical technology act as a barrier to survival.
Supporting Data and Impact
A recent clinical study conducted on the device yielded promising results. Researchers observed that the Mkanda Salama successfully halted postpartum bleeding in 73% of subjects within a 20-minute window. By focusing on accessibility, Kija is effectively challenging the health inequities that disproportionately impact women in the Global South, offering a scalable model for emergency obstetric care.
2. Xiao Yang: The Art of the Interface
The history of brain-computer interfaces (BCIs) is marked by a fundamental friction: the rigid, invasive nature of electrodes versus the delicate, fluid architecture of the human brain. While current technology has enabled breakthroughs in treating neurological disorders, the implantation process often results in localized trauma to brain tissue.
Kirigami-Inspired Innovation
Xiao Yang, 34, is shifting the design language of neural implants. Her approach centers on creating ultra-small, flexible electrodes that mimic the morphology of neurons themselves, significantly reducing the "foreign body" response within the brain.
Drawing inspiration from kirigami—the traditional Japanese art of creating intricate, three-dimensional structures through precise paper cuts—Yang has engineered sheets of electrodes with a honeycombed, spiral-basket architecture. This design allows the electrode array to be both structurally robust and highly conformable to the irregular surface of the brain. She is currently utilizing these arrays to study the activity of brain cells in laboratory settings, providing neuroscientists with a high-fidelity window into neural networks that was previously unattainable.
3. Sarah Grandinette: Personalized Gene Editing
The case of Kyle "KJ" Muldoon Jr. represents the frontier of precision medicine. Born in 2024 with a rare and life-threatening genetic disorder, KJ’s survival was contingent on the development of a therapeutic intervention that did not yet exist.
A Chronology of a Breakthrough
Sarah Grandinette, 26, played a pivotal role in the team that translated theoretical gene editing into a tangible cure. The process was a rigorous exercise in personalized medicine:
- Model Creation: Grandinette engineered cells containing KJ’s specific genetic variant.
- Screening: These cells served as the testing ground for various gene-editing approaches.
- Preclinical Validation: The most successful candidates were rigorously tested in mouse and primate models to ensure safety and efficacy.
- Clinical Administration: At seven months old, KJ received the first dose of the bespoke therapy.
The result was a medical success story. Following the treatment, KJ showed significant improvement and was discharged from the hospital. "He is doing pretty great," Grandinette reports, underscoring the potential for gene-editing platforms to move beyond one-size-fits-all treatments toward therapies designed for the individual patient.
4. Yuancheng (Ryan) Lu: The Science of Age Reversal
Perhaps no field in biotechnology carries as much public fascination—or skepticism—as longevity research. Central to this field is the concept of "reprogramming": the effort to reset the biological clock of cells, returning them to a more youthful, embryonic state.
From Mice to Men
In 2020, a landmark study published in Nature by Yuancheng (Ryan) Lu, 34, and his collaborators demonstrated that a reprogramming therapy could restore vision in aged, blind mice. By resetting the epigenetic markers of the retinal cells, the team effectively reversed vision loss associated with aging.
Official Progression and Clinical Trials
The leap from mouse models to human therapeutics is the ultimate test of any longevity intervention. Life Biosciences, the organization spearheading the commercial development of this technology, confirmed that human clinical trials began in June of this year. By dosing the first human volunteer, the company is testing whether the regenerative potential observed in the lab can safely and effectively treat age-related eye diseases in human patients.
5. Samuel King: The Generative AI Virus
The integration of generative artificial intelligence into synthetic biology has opened a new frontier: the design of life-like entities from the ground up. Samuel King, 27, has pushed the boundaries of this field by using AI models to craft the genetic blueprints for bacteriophages—viruses that specifically target and infect bacteria.
Redefining Bacteriophages
Last year, King utilized generative AI to conceptualize novel viral structures, which were then synthesized into physical DNA strands. In laboratory experiments, these AI-designed entities proved capable of self-replication and successfully targeted bacterial cells.
Broader Implications
While viruses are not "alive" in the biological sense, their utility is immense. King envisions a future where AI-designed biological agents serve as the next generation of antimicrobial drugs, effectively combating antibiotic-resistant bacteria. Beyond medicine, the implications extend to environmental science, with the potential for engineered biological entities to act as "scrubbers" for industrial pollution.
Implications for the Biotech Ecosystem
The work of these five innovators suggests a major shift in the trajectory of the life sciences. Several key themes emerge from their collective efforts:
- Democratization of Tech: Kija’s work reminds us that the most profound technological impact often comes from affordability and accessibility rather than raw complexity.
- Bio-Mimicry: Yang’s use of traditional art forms to solve modern engineering problems highlights a growing trend of interdisciplinary synthesis in biotech.
- The Velocity of Precision Medicine: Grandinette’s success with KJ highlights how quickly we are moving from diagnosis to "bespoke" genetic treatment, a development that could transform the standard of care for rare diseases.
- The AI-Biology Convergence: King and Lu represent two sides of the same coin: one using AI to create novel biological tools, the other using our understanding of cellular biology to fundamentally alter the aging process.
As these researchers continue to mature in their respective fields, the broader biotech community faces the challenge of scaling these innovations. The transition from a "cool idea" to a clinically approved, widely available product is the most difficult hurdle in biotechnology. However, as the 2026 MIT Technology Review cohort demonstrates, the next generation of scientists is not only aware of these challenges—they are actively engineering the solutions.
For those interested in following the trajectory of these innovators, the complete list of this year’s 35 Innovators Under 35 can be found via the MIT Technology Review digital archives. This report is part of a series originally featured in The Checkup, MIT Technology Review’s weekly newsletter covering the latest in global biotechnology.
